U.S. Congress legislation · 119th Congress
HB10628: Biosimilars Access and Affordability Act
Status: In committee, September 28, 2026
To amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medicare program.
What the bill says
To amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medicare program.
From the introduced text, September 28, 2026:
A BILL To amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medicare program. SECTION 1. Short title This Act may be cited as the Biosimilars Access and Affordability Act . SECTION 2. Change of when biosimilars are eligible for price negotiations (a) In general Section 1192 of the Social Security Act ( 42 U.S.C. 1320f-1 ) is amended-- (1) in subsection (c)-- (A) in paragraph (1), in the matter preceding subparagraph (A), by striking such year and each subsequent year beginning before the first year that begins at least 9 months and inserting the year of the selected drug publication date for such initial price applicability year and each subsequent year, except that a drug or biological product shall no longer be a selected drug beginning on the first day of the year that begins ; and (B) in paragraph (2)-- (i) in subparagraph (B), by striking or during the negotiation period with respect to such initial price applicability year and inserting the first day of such initial price applicability year ; and (ii) in the flush text following subparagraph (B)-- (I) by striking and shall continue and inserting if such negotiation period has not yet ended, shall not have its maximum fair price or the explanation …
Sponsors
- Nicholas Langworthy (R, HD-023) · primary sponsor
- Jake Auchincloss (D, HD-004)
- John Joyce (R, HD-013)
- Linda Sanchez (D)
- Scott Peters (D, HD-CA-50)
- Rudolph Yakym III (R, HD-IN-2)
- Nathaniel Moran (R, HD-001)
- Kevin Mullin (D, HD-CA-15)
- Jimmy Panetta (D)
- Donald Davis (D, HD-001)
Latest actions
- : Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- : Introduced in House
Subjects: Health
Common questions
- What is HB10628?
- HB10628 is a bill in Congress (119th Congress): Biosimilars Access and Affordability Act.
- What does HB10628 do?
- In its own words: To amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medicare program.
- What is the status of HB10628?
- In committee as of September 28, 2026. Latest action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (September 28, 2026).
- Who sponsored HB10628?
- Nicholas Langworthy (R, HD-023), with 9 co-sponsors.
- Where is the official record for HB10628?
- On the Congress website: https://www.congress.gov/bill/119th-congress/house-bill/10628
Source: official Congress record. Tracked by Delilah, AI for legislation across all 50 states and Congress.